Conatus
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Conatus and buy or sell other stocks, ETFs, and their options commission-free!About CNAT
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases.
CEOSteven J. Mento, PhD
CEOSteven J. Mento, PhD
Employees—
Employees—
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2005
Founded2005
Employees—
Employees—
CNAT Key Statistics
Market cap48.10K
Market cap48.10K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume1.24K
Average volume1.24K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.215
52 Week high$0.215
52 Week low$0.0002
52 Week low$0.0002
Stock Snapshot
The current Conatus(CNAT) stock price is $0.56, with a market capitalization of 48.1K.
On 2025-11-06, Conatus(CNAT) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Conatus(CNAT) stock has reached 0, versus its average volume of 1.24K.
Over the past 52 weeks, Conatus(CNAT) stock has traded between a high of $0.22 and a low of $0.00.
Over the past 52 weeks, Conatus(CNAT) stock has traded between a high of $0.22 and a low of $0.00.
People also own
Based on the portfolios of people who own CNAT. This list is generated using Robinhood data, and it’s not a recommendation.